Inventor · disambiguated record
Cai Gu Huang
Also filed as: HUANG CAI · HUANG CAI GU
9 granted patents·36 pending applications·4 citations·filing 2007–2024
78Inventor score
Files withHUANG CAI GU24ANOVENT PHARMACEUTICAL U S LLC6GUANGZHOU ANOBRI PHARMACEUTICAL CO LTD4MAI DE LTD3SUNOVION PHARMACEUTICALS INC3
Top patents by PatentIndex Score
45 records- 0180US7820716B2Crystalline polymorphs of desvenlafaxine succinate and their preparationsMAI DE LTD·Filed 2007·Granted Oct 26, 2010·2 cites·21 claims
- 0266US11369760B2Inhalation atomizer comprising a blocking function and a counterANOVENT PHARMACEUTICAL U S LLC·Filed 2017·Granted Jun 28, 2022·1 cites·14 claims
- 0362US11304897B2Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatateANOVENT PHARMACEUTICAL U S LLC·Filed 2021·Granted Apr 19, 2022·0 cites·20 claims
- 0462US2025070522A1Adapter compatible with many types of plug pinsDONGGUAN WONTRAVEL ELECTRIC CO LTD·Filed 2024·Application pending·0 cites
- 0559US8957114B2Formulations, salts and polymorphs of transnorsertraline and uses thereofLAUGHLIN SHARON M·Filed 2010·Granted Feb 17, 2015·1 cites·8 claims
- 0657US11304901B2Liposome formulation of fluticasone furoate and method of preparationANOVENT PHARMACEUTICAL U S LLC·Filed 2020·Granted Apr 19, 2022·0 cites·14 claims
- 0755US2025057866A1A synergistic pharmaceutical composition and its antiviral useGUANGZHOU ANOBRI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0855US2025270318A1Multispecific antibodies and uses thereofAB THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0955US2025074867A1Novel cationic lipid compoundsGUANGZHOU ANOBRI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1054US11083693B1Liposome formulation of vilanterol trifenatateHUANG CAI GU·Filed 2021·Granted Aug 10, 2021·0 cites·12 claims
- 1153US2025002529A1Novel deuterated cyano compounds, preparation methods, compositions and applicationsGUANGZHOU ANOBRI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1252US2009247532A1Crystalline polymorph of sitagliptin phosphate and its preparationMAE DE LTD·Filed 2009·Application pending·0 cites
- 1351US9114086B2Coated tablets of eszopicloneSUNOVION PHARMACEUTICALS INC·Filed 2014·Granted Aug 25, 2015·0 cites·6 claims
- 1450US2008038332A1Stable pharmaceutical formulation comprising atorvastatin calciumHUANG CAI GU·Filed 2007·Application pending·0 cites
- 1549US11642333B2Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromideANOVENT PHARMACEUTICAL U S LLC·Filed 2020·Granted May 9, 2023·0 cites·24 claims
- 1648US2008004313A1Preparation of crystalline polymorphs of rimonabant hydrochlorideMAI DE LTD·Filed 2007·Application pending·0 cites
- 1748US2021393663A1Pharmaceutical formulation containing active metabolites of remdesivir or its analog for inhalationHUANG CAI GU·Filed 2021·Application pending·0 cites
- 1848US2021346288A1Pharmaceutical formulation containing active metabolites of remdesivir for inhalationHUANG CAI GU·Filed 2021·Application pending·0 cites
- 1948US2022031712A1Preparation of a pharmaceutical composition of olodaterol and budesonideHUANG CAI GU·Filed 2021·Application pending·0 cites
- 2048US2009215787A1Preparations of new polymorphic forms of varenicline tartrateMAI DE LTD·Filed 2009·Application pending·0 cites
- 2147US2021252027A1Pharmaceutical formulation containing remdesivirHUANG CAI GU·Filed 2021·Application pending·0 cites
- 2247US2018071230A1Formulations, salts and polymorphs of transnorsertraline and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2347US2021220367A1Inhalable formulation of a solution containing glycopyrrolate and olodaterol hydrochlorideHUANG CAI GU·Filed 2021·Application pending·0 cites
- 2447US2021275449A1Inhalable Formulation of a Solution Containing Glycopyrronium BromideHUANG CAI GU·Filed 2021·Application pending·0 cites
- 2547US2021401855A1Pharmaceutical formulation containing combination of m3 antagonist-beta-2 agonist and inhaled corticosteroidsHUANG CAI GU·Filed 2021·Application pending·0 cites
- 2646US11365248B2Formulation of tocilizumab and method for treating COVID-19 by inhalationANOVENT PHARMACEUTICAL U S LLC·Filed 2021·Granted Jun 21, 2022·0 cites·5 claims
- 2746US2021353650A1Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalationHUANG CAI GU·Filed 2021·Application pending·0 cites
- 2845US2021030868A1Formulation of antibody based drugs for treating lung cancer by inhalationHUANG CAI GU·Filed 2020·Application pending·0 cites
- 2945US2021322309A1Inhalable Formulation of a Solution Containing OlodaterolHUANG CAI GU·Filed 2021·Application pending·0 cites
- 3045US2021386730A1Pharmaceutical formulation containing glycopyrrolate and indacaterol maleateHUANG CAI GU·Filed 2021·Application pending·0 cites
- 3145US2021393521A1Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonideHUANG CAI GU·Filed 2021·Application pending·0 cites
- 3244US2022064328A1Formulation of nanoantibody based drugs and a method for treating thrombotic thrombocytopenic purpura by inhalationANOVENT PHARMACEUTICAL U S LLC·Filed 2021·Application pending·0 cites
- 3344US2021322311A1Inhalable Formulation of a Solution Containing Tiotropium Bromide and OlodaterolHUANG CAI GU·Filed 2021·Application pending·0 cites
- 3444US2024351974A1Novel cationic lipid compoundsGUANGZHOU ANOBRI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3544US2021322310A1Inhalable Formulation of a Solution Containing Tiotropium BromideHUANG CAI GU·Filed 2021·Application pending·0 cites
- 3643US2021290568A1Inhalable formulation of a solution containing levalbuterol tartrateHUANG CAI GU·Filed 2021·Application pending·0 cites
- 3742US2020375945A1Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromideHUANG CAI GU·Filed 2020·Application pending·0 cites
- 3842US2021030978A1Cartridge with single-layer container and its nozzle-shaped cap for nebulization inhalationHUANG CAI GU·Filed 2020·Application pending·0 cites
- 3942US2020405700A1Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromideHUANG CAI GU·Filed 2020·Application pending·0 cites
- 4042US2021205223A1Propellant-free formulation for inhalationHUANG CAI GU·Filed 2020·Application pending·0 cites
- 4140US2020324064A1Inhalation Device for Administering Powdered Pharmaceutical CompositionHUANG CAI GU·Filed 2020·Application pending·0 cites
- 4240US2015196502A1Formulations, salts and polymorphs of transnorsertraline and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4339US2021403568A1Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalationHUANG CAI GU·Filed 2021·Application pending·0 cites
- 4436US2010221338A1Coated Tablets Of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-Oxo-6,7-Dihydro-5H-Pyrrolo[3,4-b]Pyrazine And Methods For Measuring Effectiveness Of CoatingSEPRACOR INC·Filed 2010·Application pending·0 cites
- 4533US2018344956A1Inhaler Device for Administering Powered Pharmaceutical Compositions via InhalationHUANG CAI GU·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Cai Gu Huang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →